ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,743Medicare Part D Prescriptions Filled, Including Refills

Rank: 555 out of 5176

$501K Total Retail Price of All Prescriptions

Rank: 1170 out of 5176

414 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
73% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 414 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

11% of this provider’s 414 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 9,353 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
FUROSEMIDE 499 446 1 8
LEVOTHYROXINE SODIUM 428 396 2 4
AMLODIPINE BESYLATE 407 362 3 2
SIMVASTATIN 365 325 4 1
METOPROLOL TARTRATE 337 280 5 6
LISINOPRIL 337 282 5 5
GABAPENTIN 327 264 7 21
CITALOPRAM HBR 288 266 8 31
DONEPEZIL HCL 285 272 9 28
MIRTAZAPINE 283 265 10 45
WARFARIN SODIUM 247 217 11 13
POTASSIUM CHLORIDE 227 217 12 34
NAMENDA 175 175 13 47
TAMSULOSIN HCL 170 152 14 20
QUETIAPINE FUMARATE 166 148 15 75
OMEPRAZOLE 131 113 16 3
HYDROCODONE-ACETAMINOPHEN 129 100 S3 17 27
METFORMIN HCL 120 99 18 7
ATENOLOL 107 96 19 12
JANTOVEN 103 103 20 106
ALENDRONATE SODIUM 102 92 21 18
DIVALPROEX SODIUM 102 90 21 104
HYDROCHLOROTHIAZIDE 95 93 23 10
CARVEDILOL 93 74 24 24
LOSARTAN POTASSIUM 91 91 25 14
SERTRALINE HCL 90 80 26 30
METOPROLOL SUCCINATE 86 86 27 11
ATORVASTATIN CALCIUM 85 62 28 9
PREDNISONE 83 60 29 52
RISPERIDONE 83 71 29 78
CLOPIDOGREL 81 64 31 26
GLIPIZIDE 78 66 32 63
TRAZODONE HCL 74 74 33 71
ROPINIROLE HCL 72 70 34 208
CYMBALTA 69 42 35 90
ESCITALOPRAM OXALATE 67 59 36 89
PRAVASTATIN SODIUM 63 51 37 23
KLOR-CON M20 63 51 37 129
SUCRALFATE 61 47 39 303
DIGOXIN 59 59 40 56
CRESTOR 58 39 41 15
ALBUTEROL SULFATE 56 45 42 99
PANTOPRAZOLE SODIUM 56 44 42 61
LEVETIRACETAM 55 39 44 92
EXELON 54 54 45 162
ENALAPRIL MALEATE 50 47 46 22
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.